Evaluating bone marrow function in patients with CLL and MBL compared to healthy individuals
Official title: Hematopoiesis in Monoclonal B Cell Lymphocytosis (MBL) and B-Chronic Lymphocytic Leukemia (CLL) Versus Healthy Age-Matched Control Subjects
Run by Mayo Clinic · NCT06536452 · Data updated 2026-11-12
This study is trying to see how bone marrow function is different in people with Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL) compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | November 18, 2016 |
| Main results expected | November 18, 2028 |
| Study ends | November 18, 2028 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT06536452 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with CLL or MBL, as well as healthy age-matched controls.
✕Probably not a fit
Patients under 40 years old or those with a diagnosis of CLL or MBL who do not meet the inclusion criteria will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess how bone marrow hematopoiesis is affected in patients with Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL). The study will analyze the cellular and mechanistic basis of hematopoietic dysfunction in untreated patients and investigate how B cell-derived products from these patients influence the differentiation and function of Hematopoietic Stem and Progenitor Cells (HSPCs). Utilizing a transgenic mouse model, researchers will further explore the impact of patient-derived cellular products on bone marrow hematopoiesis. Participants will undergo blood sample collection and bone marrow aspiration, with their medical records reviewed for comprehensive analysis.
Why it matters
Potential benefit: If successful, this study could enhance understanding of hematopoietic dysfunction in CLL and MBL, potentially leading to improved treatment strategies.
How similar studies have gone: Other studies have explored hematopoiesis in similar contexts, but this specific approach using patient-derived products in a transgenic model is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects in the CLL cohort who are eligible for these studies will have a clinically established diagnosis of CLL as assessed by flow cytometry and will include subjects who * Remain untreated * Are currently being treated * Who have already been treated * Subjects in the MBL cohort will have a clinically established diagnosis of MBL * Healthy age-matched control subjects * Healthy younger control subjects aged \> 40 years Exclusion Criteria: * Anyone under 40 * Healthy control subjects must not have a diagnosis of CLL or MBL
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Neil E. Kay, M.D. — Mayo Clinic in Rochester
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL
This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.
-
Nemtabrutinib and venetoclax in untreated CLL/SLL
This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
NX-5948 plus other medicines for B-cell cancers
This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.
-
NX-5948 vs Pirtobrutinib in R/R CLL/SLL
This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.